Daily Market Digest Thur 6 Jan: Pathology stocks fall as Aus Govt votes in rapid antigen, tech stocks see carnage, Pfizer due for boost

Daily Market Digest Thur 6 Jan: Pathology stocks fall as Aus Govt votes in rapid antigen, tech stocks see carnage, Pfizer due for boost

Equities 4 minutes to read
Jessica Amir

Australian Market Strategist

Summary:  Asian and Australian markets follow US lower as the Fed hints interest rates hikes could come quicker and faster. US tech stocks crumble, taking selling in tech and profitless stocks to a 10 year high. Pathology companies fall from record highs as the Australian Fed Gov says Aussies can take rapid antigen tests over PCR. Pfizer’s booster is approved and its share look ripe for a rally. Plus, why lithium, EVs and oil stocks are revving up.


Firstly  -  what you need to know now and consider

  • Beware of mounting tech and profitless stock selling: Professional investors spent December selling high-growth, high-valuation stocks ahead of the US Fed hiking rates in 2022, AND overnight, SELLING INTENSIFIED after the Federal flagged the chance of earlier and faster interest rate hikes. Sales in profitless tech stocks hit its highest level in 10 year. The technical indicators suggest the Nasdaq for instance is susceptible to another pull back on the hourly and daily chart.
  • In Australia, Afterpay, which was the biggest tech stock in Australia has today fallen 9.7% to $72.66, its lowest price since September 2020 as trading volume in the stock doubled its 20-day average, showing that investors are running for the hills out of stocks that carry high -debt and don’t make a profit. Afterpay shares have tanked 35% year-on-year and Morgans cut Afterpay’s price target by 31% following the founders and insiders reducing their holdings in the buy now pay later giant. It also follows Tencent Holdings reducing its stake in Afterpay to 4.86% last year. Afterpay shares on the hourly, daily and weekly chart suggest further selling could come for holders of Afterpay. However the RSI indicators the stocks has been oversold. So beware if you are trading this.
  • Health companies are in focus again for two reasons, firstly Pfizer and BioNTech’s booster got US approval to be used in teens (people aged 12 to 17). The CDC has already approved Pfizer-BioNTech’s booster and Moderna’s booster for those over 18, and said they are preferred over Johnson & Johnson. Pfizer’s shares have been hovering around the same level since late October, however now the daily and weekly technical indicators such as the MACD and the RSI look interesting suggesting, Pfizer shares could be due for a rally.
  • The second reason healthcare stocks will be in focus for the rest of the week is because The Australian government wound back testing requirements - so people will now be able to take a rapid antigen tests without the need for a PCR test. Meaning, pathology giants like Sonic Healthcare and Australian Clinical Labs will be tested by investors and both shares in SHL and ACL are likely to fall further from their record all-time highs.
  • Oil stocks again a focus with  the price of oil trading bat $77.17 (Crude WTI ), and now facing further upward pressure as Mexico plans to halt crude exports by 2023. If this proves true it will remove one of the largest oil sellers from the market and push long-date oil prices higher. Our group thinking is that the price of oil could soon hit $100 a barrel as demand improves while weather extremities worsen.
  • In other big news, Lithium and battery minerals and electric vehicle stocks have also been thrust into the limelight this year as some of the best performers so far in 2022. Pilbara Minerals, and Alkem on the ASX are both of are up over 1% in 3 days. The battery minerals and EV ETF ACDC is flat, while overseas, the gains are far more exciting. For the worlds biggest auto makers; Toyota shares are up 5.7%, and VW shares are up 8.3% year to date.  One of the reasons is that last month, within five days of each other - both Toyota Motor Corp and Volkswagen laid out mass production plans to splurge $170 billion over the coming years to preserve their claim on an industry and transition from internal combustion engines to electric. Interestingly VW and Toyota sold 10 or 11 cars for every one Tesla sold in 2021. Despite that, Tesla is the most valuable listed car company.

Secondly, watch companies with Australian analyst rating changes

  • PDL: Pendal Group Raised to Outperform at Credit Suisse; PT A$7.20
  • APT: Morgans cut its PT on the stock by 31%.
  • PME: Pro Medicus Cut to Reduce at Morgans Financial Limited

Thirdly, watch companies in the news

  • Paladin shares pump 4% putting uranium companies back in the limelight; Uranium prices appear likely to rise as Kazakhstan, the world’s largest producer of the radioactive metal, struggles to cope with deadly protests that pose the biggest challenge to the country’s leadership in decades.
  • Serbia Seeks Safety Assurances on Rio Tinto Lithium Project: Serbia won’t let Rio Tinto mine its lithium without assurances that the company’s $2.4 billion project in the Balkan country is environmentally safe even as it offers huge economic benefits, a top government official says. Rio, committed the funds in July with plans to tap into one of Europe’s largest lithium deposits as global demand grows for battery material.
  • BHP (AU): ‘Thirsty Copper Mines Turn to the Sea as Chile Water Debate Rages
  • Ramsay Health Care (RHC AU): will recruit 550 graduate nurses next month in effort to combat chronic labor shortages: Australian
  • Aristocrat's Playtech Bid Likely to Be Rejected: Playtech Adjourns Holder Vote on Aristocrat Offer to Feb. 2. Playtech’s current share price (731.5p) suggests investors will reject Aristocrat’s 680p/share bid, even if a rival offer from JKO Play fails to materialize, writes Ivor Jones, an analyst at Peel Hunt (hold).
  • The Bank of Queensland’s ROE May Stick at 8% Due to Weak Revenue and Branch Assets: BOQ's ‘Revenue-to-Assets Inferior’.
  • Shareholder Events: WMC AU

Markets -  The numbers

  • Global Markets; In the US Dow Average down 0.2% to 36,713.26, the Nasdaq fell 3.3%. In Europe  FTSE 100 rose 0.6% to 7,341.66. The German Dax rose 0.7%.
  • CommoditiesIron ore futures are up 1.2% to $125.75. Gold spot up 0.3% to $1,819.70, Brent futures up 1.0% to $80.79/bbl
  • Currencies: Euro up 0.3% to $1.1320, Aussie up 0.1% to 0.7244 per US$, Kiwi little changed at 0.6813 per US$
  • Bonds: U.S. 10-year yield rose 4.6bps to 1.6929%. Australia 3-year bond yield rose 0.5bps to 1.15%, Australia 10-year bond yield rose 4bps to 1.79%
Disclaimer

The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/legal/disclaimer/saxo-disclaimer)
- Full disclaimer (https://www.home.saxo/en-mena/legal/disclaimer/saxo-disclaimer)


Due to coronavirus controls, we are not able to meet with clients in our reception at present, unless by appointment in exceptional circumstances. We remain at your service on the phone and email details below. Thank you for your understanding.

Please expect very long waiting times on the line when calling us, we advise you to send us an email instead.

Contact Saxo

Select region

UAE
UAE

Trade responsibly
All trading carries risk. Read more. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more

Saxo Bank A/S is licensed by the Danish Financial Supervisory Authority and operates in the UAE under a representative office license issued by the Central bank of the UAE.

The content and material made available on this website and the linked sites are provided by Saxo Bank A/S. It is the sole responsibility of the recipient to ascertain the terms of and comply with any local laws or regulation to which they are subject.

The UAE Representative Office of Saxo Bank A/S markets the Saxo Bank A/S trading platform and the products offered by Saxo Bank A/S.